Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
-
- Emi Takashita
- National Institute of Infectious Diseases, Tokyo, Japan
-
- Noriko Kinoshita
- National Center for Global Health and Medicine, Tokyo, Japan
-
- Seiya Yamayoshi
- University of Tokyo, Tokyo, Japan
-
- Yuko Sakai-Tagawa
- University of Tokyo, Tokyo, Japan
-
- Seiichiro Fujisaki
- National Institute of Infectious Diseases, Tokyo, Japan
-
- Mutsumi Ito
- University of Tokyo, Tokyo, Japan
-
- Kiyoko Iwatsuki-Horimoto
- University of Tokyo, Tokyo, Japan
-
- Peter Halfmann
- University of Wisconsin–Madison, Madison, WI
-
- Shinji Watanabe
- National Institute of Infectious Diseases, Tokyo, Japan
-
- Kenji Maeda
- National Center for Global Health and Medicine, Tokyo, Japan
-
- Masaki Imai
- University of Tokyo, Tokyo, Japan
-
- Hiroaki Mitsuya
- National Center for Global Health and Medicine, Tokyo, Japan
-
- Norio Ohmagari
- National Center for Global Health and Medicine, Tokyo, Japan
-
- Makoto Takeda
- National Institute of Infectious Diseases, Tokyo, Japan
-
- Hideki Hasegawa
- National Institute of Infectious Diseases, Tokyo, Japan
-
- Yoshihiro Kawaoka
- University of Tokyo, Tokyo, Japan
書誌事項
- 公開日
- 2022-04-14
- 権利情報
-
- http://www.nejmgroup.org/legal/terms-of-use.htm
- DOI
-
- 10.1056/nejmc2201933
- 公開者
- Massachusetts Medical Society
この論文をさがす
収録刊行物
-
- New England Journal of Medicine
-
New England Journal of Medicine 386 (15), 1475-1477, 2022-04-14
Massachusetts Medical Society